IL298065A - Il-2 fusion polypeptide compositions and methods of making and using the same - Google Patents

Il-2 fusion polypeptide compositions and methods of making and using the same

Info

Publication number
IL298065A
IL298065A IL298065A IL29806522A IL298065A IL 298065 A IL298065 A IL 298065A IL 298065 A IL298065 A IL 298065A IL 29806522 A IL29806522 A IL 29806522A IL 298065 A IL298065 A IL 298065A
Authority
IL
Israel
Prior art keywords
composition
polypeptide
certain embodiments
aqueous solution
nacl
Prior art date
Application number
IL298065A
Other languages
English (en)
Hebrew (he)
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of IL298065A publication Critical patent/IL298065A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL298065A 2020-05-11 2021-05-10 Il-2 fusion polypeptide compositions and methods of making and using the same IL298065A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063022853P 2020-05-11 2020-05-11
PCT/US2021/031611 WO2021231316A1 (en) 2020-05-11 2021-05-10 Il-2 fusion polypeptide compositions and methods of making and using the same

Publications (1)

Publication Number Publication Date
IL298065A true IL298065A (en) 2023-01-01

Family

ID=78524918

Family Applications (1)

Application Number Title Priority Date Filing Date
IL298065A IL298065A (en) 2020-05-11 2021-05-10 Il-2 fusion polypeptide compositions and methods of making and using the same

Country Status (12)

Country Link
US (1) US20210371486A1 (enExample)
EP (1) EP4149515A4 (enExample)
JP (1) JP2023525565A (enExample)
KR (1) KR20230009446A (enExample)
CN (1) CN115916242A (enExample)
AU (1) AU2021270745A1 (enExample)
BR (1) BR112022022764A2 (enExample)
CA (1) CA3172871A1 (enExample)
IL (1) IL298065A (enExample)
MX (1) MX2022014164A (enExample)
TW (1) TW202207970A (enExample)
WO (1) WO2021231316A1 (enExample)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1292686C (en) * 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
SK11142002A3 (sk) * 1999-12-30 2004-09-08 Chiron Corporation Liečivo na podávanie interleukínu-2 a stabilizovaný lyofilizovaný alebo sprejovo sušený farmaceutický prostriedok s obsahom interleukínu-2
CN1816356A (zh) * 2003-05-14 2006-08-09 免疫原公司 药物缀合物组合物
JP2006137678A (ja) * 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物
US9156897B2 (en) * 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
US10016415B2 (en) * 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
AU2015364396B2 (en) * 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
WO2019019998A1 (zh) * 2017-07-25 2019-01-31 江苏恒瑞医药股份有限公司 一种il-15蛋白复合物药物组合物及其用途
US20210038684A1 (en) * 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy
BR112022007158A2 (pt) * 2019-10-18 2022-07-05 Alkermes Pharma Ireland Ltd Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
EP4093755A4 (en) * 2020-01-24 2024-07-31 Alkermes Pharma Ireland Limited PURIFICATION PROCESSES

Also Published As

Publication number Publication date
KR20230009446A (ko) 2023-01-17
CA3172871A1 (en) 2021-11-18
CN115916242A (zh) 2023-04-04
EP4149515A4 (en) 2023-12-06
BR112022022764A2 (pt) 2023-01-17
JP2023525565A (ja) 2023-06-16
MX2022014164A (es) 2023-02-22
TW202207970A (zh) 2022-03-01
AU2021270745A1 (en) 2022-12-15
WO2021231316A1 (en) 2021-11-18
US20210371486A1 (en) 2021-12-02
EP4149515A1 (en) 2023-03-22

Similar Documents

Publication Publication Date Title
JP5503543B2 (ja) クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物
US20120230913A1 (en) Protein nanoparticle dispersions
IL298382A (en) Nectin-4-specific bicyclic peptide ligands and their uses
IL263630B2 (en) Stable liquid pharmaceutical preparation
IL266264B1 (en) Adeno-associated virus formulations
NZ567685A (en) A Factor IX formulation for injection comprising sodium chloride
IL265665B1 (en) Room temperature stable lyophilized protein
IL277241B (en) Liquid pharmaceutical composition
CA3156812A1 (en) Anti-connexin antibody formulations
IL297326A (en) Pharmaceutical preparations and pharmaceutical products of human interleukin-15 hydrometers (ethyl-15)
IL276960A (en) Lyophilized formulations for factor xa antidote
IL292176A (en) Humanized antibody and method for using it
IL321955A (en) Injectable formulation containing a biopharmaceutical and a polyacrylamide-based copolymer
IL298065A (en) Il-2 fusion polypeptide compositions and methods of making and using the same
Nguyen et al. Impact of sugar molecular weight on the miscibility and stability of lyophilized and spray-dried protein formulations
IL298064A (en) Il-2 fusion polypeptide compositions and methods of making and using the same
CN116077646B (zh) 一种抗冠状病毒s蛋白的抗体制剂及其制备方法和用途
IL289219B2 (en) Composition and methods for stabilizing liquid protein formulations
KR20240099278A (ko) 에프룩시페르민의 제약 조성물
IL322410A (en) Stable protein complexes containing an antibody against PD1
IL324512A (en) Formulations to stabilize virus-based therapeutics
IL313777A (en) Complement factor-i formulations
EA045592B1 (ru) Жидкий препарат, содержащий антитело к il-17